Join
Live feed
·
PRReleasevia Quantisnow
Relmada Therapeutics Inc. logo

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

ByQuantisnow·Wall Street's wire, on your screen.
RLMD· Relmada Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLMD (Relmada Therapeutics Inc.) and more on Quantisnow.